Overview of Merger Completion

Paragon Care Limited (ASX: $PGC) has successfully completed the merger with CH2 Holdings Pty Limited (CH2) on 3 June 2024. As part of the merger, Paragon has acquired all of the issued share capital of CH2 and issued 943,524,072 ordinary shares to specific trustees. This transformative transaction is anticipated to establish Paragon as a prominent healthcare wholesaler, distributor, and manufacturer operating across healthcare markets in the Asia Pacific region. The board of directors has also undergone significant changes, with new appointments and resignations.

Executive Commentary on Merger and Leadership Changes

The completion of the merger with CH2 Holdings Pty Limited marks a significant milestone for Paragon Care Limited. This strategic move is expected to position Paragon as a leading player in the healthcare industry across the Asia Pacific region. The changes in the board of directors and the appointment of David Collins as the new CEO reflect our commitment to driving growth and diversification. We are confident that Mr. Collins' extensive experience in the healthcare industry will contribute to the continued success of the merged entity.

Summary of Merger and Future Outlook

The completion of the merger with CH2 Holdings Pty Limited signifies a pivotal moment for Paragon Care Limited, as it sets the stage for the company to emerge as a prominent healthcare wholesaler, distributor, and manufacturer in the Asia Pacific region. The leadership changes, including the appointment of David Collins as the new CEO, demonstrate the company's strategic vision for growth and expansion. With a focus on leveraging Mr. Collins' expertise and experience, Paragon aims to capitalize on the opportunities presented by the merger and further strengthen its position in the healthcare industry. The merger is expected to drive synergies and enhance the company's capabilities, paving the way for sustained growth and value creation.